'Rule­book of mi­cro­bial ecol­o­gy': Pi­anists launch Con­cer­to to treat eczema, pro­tect crops and get rid of BO

The mi­cro­bio­me world, at least in drug R&D, has had some hic­cups this year, with Flag­ship’s Kalei­do Bio­sciences shut­ting down and DermBiont piv­ot­ing away from the world of mi­crobes, but there’s al­ways room for new in­no­va­tion.

In steps Con­cer­to Bio­sciences, which came out with a $23 mil­lion Se­ries A this week. Mer­ck KGaA’s VC arm, Sa­far Part­ners and Hori­zons Ven­tures are all back­ing the Cam­bridge, MA start­up hop­ing to treat atopic der­mati­tis, pro­tect crops and get rid of bad odor in those sweaty armpits.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER